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Abstract 
Alzheimer’s disease is a highly heritable, common neurodegenerative disease characterised 
neuropathologically by the accumulation of β-amyloid plaques and tau-containing 
neurofibrillary tangles. In addition to the well-established risk associated with the APOE locus, 
there has been considerable success in identifying additional genetic variants associated with 
Alzheimer’s disease. Major challenges in understanding how genetic risk influences the 
development of Alzheimer’s disease are clinical and neuropathological heterogeneity, and the 
high level of accompanying comorbidities. We report a multimodal analysis integrating 
longitudinal clinical and cognitive assessment with neuropathological data collected as part of 
the Brains for Dementia Research (BDR) study to understand how genetic risk factors for 
Alzheimer’s disease influence the development of neuropathology and clinical performance. 
693 donors in the BDR cohort with genetic data, semi-quantitative neuropathology 
measurements, cognitive assessments and established diagnostic criteria were included in this 
study. We tested the association of APOE genotype and Alzheimer’s disease polygenic risk 
score - a quantitative measure of genetic burden - with survival, four common 
neuropathological features in Alzheimer’s disease brains (neurofibrillary tangles, β-amyloid 
plaques, Lewy bodies and TDP-43 proteinopathy), clinical status (clinical dementia rating) and 
cognitive performance (Mini-Mental State Exam, Montreal Cognitive Assessment). The APOE 
ε4 allele was significantly associated with younger age of death in the BDR cohort. Our 
analyses of neuropathology highlighted two independent pathways from APOE ε4, one where 
β-amyloid accumulation co-occurs with the development of tauopathy, and a second 
characterized by direct effects on tauopathy independent of β-amyloidosis. Although we also 
detected association between APOE ε4 and dementia status and cognitive performance, these 
were all mediated by tauopathy, highlighting that they are a consequence of the 
neuropathological changes. Analyses of polygenic risk score identified associations with 
tauopathy and β-amyloidosis, which appeared to have both shared and unique contributions, 
suggesting that different genetic variants associated with Alzheimer’s disease affect different 
features of neuropathology to different degrees. Taken together, our results provide insight into 
how genetic risk for Alzheimer’s disease influences both the clinical and pathological features 
of dementia, increasing our understanding about the interplay between APOE genotype and 
other genetic risk factors. 
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Introduction 
Alzheimer’s disease is a common neurodegenerative disease characterised clinically by 
progressive memory and cognitive decline leading to dementia and neuropathologically by β-
amyloid plaques and tau-containing neurofibrillary tangles. The most frequent manifestation 
of Alzheimer’s disease is late onset Alzheimer’s disease (LOAD) where onset occurs after the 
age of 65. LOAD is highly heritable (Gatz et al., 2006) with the most established genetic risk 
factor being variants of the APOE gene. Relative to the most common genotype (ε3/ε3), the ε4 
allele increases the risk of Alzheimer’s disease, with ε4 homozygosity associated with 
approximately 20-fold increase in risk (Farrer et al., 1997). In contrast, the ε2 allele of APOE 
has strong protective effects (Reiman et al., 2020).  Genome-wide association studies (GWAS) 
in large sample cohorts (Lambert et al., 2013; Marioni et al., 2018; Jansen et al., 2019; Kunkle 
et al., 2019) have identified additional variants in more than 40 regions of the genome which 
individually confer subtler effects on risk, but cumulatively account for a large proportion of 
genetic risk. To index an individuals’ genetic risk profile, disease-associated variants - typically 
including those below genome-wide significance - can be combined into a ‘polygenic risk 
score’ (PRS). PRSs quantify the number of genetic risk variants an individual has, weighted 
by their effect size, and have been shown to improve prediction models of Alzheimer’s disease 
(Escott-Price et al., 2015; Cruchaga et al., 2018; Escott-Price et al., 2019). Of note, the 
Alzheimer’s disease PRS has greatest predictive power where disease status has been defined 
by standardized neuropathological assessment (Escott-Price et al., 2017), and is most elevated 
in sporadic early-onset cases (Cruchaga et al., 2018).  
 
In addition to genetic prediction, PRSs provide a powerful mechanism to investigate how 
genetic risk mediates the development of symptoms, and can potentially be used to disentangle 
the primary causal features from the secondary consequences of disease. As well as being 
associated with dementia status, the Alzheimer’s disease PRS has been shown to correlate with 
mild cognitive impairment (Adams et al., 2015; Chaudhury et al., 2019), cognitive decline 
(Mormino et al., 2016; Marioni et al., 2017; Felsky et al., 2018), memory impairments 
(Mormino et al., 2016; Marioni et al., 2017), cortical thickness (Sabuncu et al., 2012; Corlier 
et al., 2018), hippocampal volume (Lupton et al., 2016; Mormino et al., 2016), cerebrospinal 
biomarkers (Martiskainen et al., 2015; Louwersheimer et al., 2016; Desikan et al., 2017), and 
neuropathology (Desikan et al., 2017; Felsky et al., 2018; Tasaki et al., 2018). The breadth of 
associations highlights the complexity of understanding the pathways from genetic risk to 
symptomatic disease. Furthermore, many of these analyses have included the APOE locus 
within the PRS, meaning their results may reflect APOE-specific effects rather than the 
consequences of a broader polygenic risk burden. To truly understand how multiple genetic 
risk factors combine to influence the interplay of the clinical, cognitive and neuropathological 
characteristics of Alzheimer’s disease, we need large, longitudinal cohorts with post-mortem 
tissue that can align genetics, clinical data and standardized neuropathological assessments. 
 
A major challenge in understanding how genetic risk influences the development of 
Alzheimer’s disease relates to clinical and neuropathological heterogeneity, and the high level 
of accompanying comorbidities associated with a diagnosis of Alzheimer’s disease. The 
presence of the neuropathological hallmarks of Alzheimer’s disease can only be confirmed 
following post-mortem brain examination.  Standardized sampling and staining methods, along 
with the introduction of a number of semi-quantitative classification schemes, each focused on 
a single neuropathological feature (Thal et al., 2002; Braak et al., 2003; Braak et al., 2006), 
promote consistency making it easier to harmonise data across brain banks and ultimately the 
reproducibility of findings across studies. It is now recognised that sporadic dementia in older 
people is predominantly due to multiple pathologies (Robinson et al., 2018). The most frequent 
comorbidity is Lewy body pathology affecting up to 50% of sporadic Alzheimer’s disease cases 
(Toledo et al., 2013). Another common comorbidity is the presence of inclusion bodies 
containing aggregates of transactive response DNA-binding protein 43 (TDP-43), particularly 
in the oldest old (Amador-Ortiz et al., 2007; Uryu et al., 2008; James et al., 2016). As well as 
influencing cognitive impairment in non-Alzheimer’s disease cases (Nag et al., 2017), these 
comorbidities contribute to the cognitive decline observed in Alzheimer’s disease cases beyond 
that associated with β-amyloid and neurofibrillary tangle pathology (Wilson et al., 2013) 
(Nelson et al., 2019), hence it is important to consider multiple neuropathological features 
simultaneously, to understand  the  processes that underlie cognitive performance in old age.  
 
The paucity of comprehensive neuropathological data in large sample cohorts has limited 
previous genetic studies of Alzheimer’s disease-associated neuropathology. To address this 
gap, the Brains for Dementia Research (BDR) cohort was established in 2007 recruiting both 
dementia patients and unaffected controls over the age of 65 to partake in routine longitudinal 
assessments collecting cognitive, clinical, lifestyle and psychometric data, prior to post-
mortem brain donation (Francis et al., 2018). The inclusion of standardized semi-quantitative 
data for a range of neuropathological features facilitates analyses into the specificity of genetic 
risk factors for the different abnormalities, and an assessment of their clinical contributions. In 
this study we report the first multimodal analysis of the BDR cohort, integrating longitudinal 
clinical and cognitive assessment with neuropathological data to explore how known genetic 
risk factors for Alzheimer’s disease influence the development of different aspects of 
neuropathology and cognitive performance in old age. We focus on four common 
neuropathological features observed in Alzheimer’s disease brain tissue: neurofibrillary 
tangles, β-amyloid plaques, Lewy bodies and TDP-43 proteinopathy. The results of this study 
provide insights into the neurobiological pathways to cognitive decline by refining our 
understanding of the complex interplay of genetic risk, clinical presentation and 
neuropathological burden. 
 
Materials and Methods 
Brains for Dementia Research (BDR) cohort description 
BDR was established in 2007 and consists of a network of six dementia research centres in 
England and Wales (King’s College London, Bristol, Manchester, Oxford, Cardiff and 
Newcastle Universities) and the associated university brain banks handling the donations 
(Cardiff brain donations were banked in London). Participants over the age of 65 were recruited 
using national and local press, TV and radio coverage, articles in charity newsletters, national 
magazines with an older following, BDR posters, leaflets, memory clinics, talks at 
carer/support groups, Women’s Institute, and the University of the Third Age. There was no 
screening to exclude or include individuals with particular diagnoses or those carrying genetic 
variants associated with neurodegenerative diseases. The cohort includes individuals with and 
without dementia, spanning the full spectrum of dementia diagnoses. Participants underwent a 
series of longitudinal cognitive and psychometric assessments and registered for brain 
donation.  An extensive description of the recruitment strategy, demographics, assessment 
protocols and neuropathic assessment procedures can be found in (Francis et al., 2018). 
 
Longitudinal cognitive and clinical assessments 
All assessments were conducted by a trained psychologist or research nurse. Exclusion criteria 
to undergo assessments included: 1) factors precluding brain donation (e.g. brain injury/trauma, 
major stroke), 2) being younger than 65 for healthy controls (except where they were 
spouses/partners of participants with dementia), 3) having insufficient English language skills 
for completing assessments, and 4) being geographically too remote from an assessment centre.  
Baseline assessments were conducted face-to-face (in the participant’s place of residence or a 
BDR centre), follow-up assessments were usually face-to-face but telephone interviews were 
also used for some healthy control participants. Follow-up interviews were annual for 
participants with cognitive impairment, and every 1 to 5 years (depending on age) for 
cognitively healthy participants. Clinical assessment was performed using the Clinical 
Dementia Rating (CDR) (Morris, 1993). Cognitive assessment measures relevant to this study 
included the Mini-Mental State Examination (MMSE) (Folstein et al., 1975) and Montreal 
Cognitive Assessment (MoCA) (Nasreddine et al., 2005).   
 
Post-mortem neuropathological assessment 
After removal, the brain was examined macroscopically and digitally recorded. After slicing, 
the brain was comprehensively sampled according to the BDR protocol by experienced 
neuropathologists in each of the five network brain banks. This protocol, arrived at by 
consensus across the BDR network and based on the BrainNet Europe initiative (Bell et al., 
2008), was used to generate a description of the regional pathology within the brain together 
with standardized scoring. In this study we considered five variables representing four 
neuropathological features: i) Braak tangle stage which captures the progression of 
neurofibrillary tangle pathology (Braak and Braak, 1991; Braak et al., 2006), ii) Thal β-amyloid 
phase which captures the regional distribution of plaques (Thal et al., 2002), iii) Consortium to 
Establish a Registry for Alzheimer’s Disease (CERAD) stage which profiles neuritic plaque 
density (Mirra et al., 1991; Montine et al., 2012), iv) Braak Lewy body stage (Braak et al., 
2003) and v) TDP-43 status (a binary indicator of the absence/presence of TDP-43 inclusions, 
as assessed by immunohistochemistry of the amygdala and the hippocampus and adjacent 
temporal cortex for phosphorylated TDP-43). All variables apart from TDP-43 were analysed 
as continuous variables, using their semi-quantitative nature to capture dose-dependent 
relationships of increasing neuropathological burden. 
 
Genetic data 
DNA extraction was performed using a standard phenol chloroform method on 100 mg of brain 
tissue. DNA quality was assessed using the Agilent 2200 TapeStation DNA integrity number 
and quantified using Nanodrop 3300 spectrometry. Genotyping was performed on the 
NeuroChip array which is a custom Illumina genotyping array with an extensive genome-wide 
backbone (n = 306,670 variants) and custom content covering 179,467 variants specific to 
neurological diseases (Blauwendraat et al., 2017). Genotype calling was performed using 
GenomeStudio (v2.0, Illumina) and quality control (QC) was completed using PLINK1.9 
(Chang et al., 2015). Individuals were excluded if either 1) they had > 5% missing data, 2) their 
genotype predicted sex using X chromosome homozygosity was discordant with their reported 
sex (excluding females with an F value > 0.2 and males with and F value < 0.8), 3) they had 
excess heterozygosity ( >3 SD from the mean), 4) they were related to another individual in 
the sample (pi hat > 0.2), where one individual from each pair of related samples was excluded 
considering data quality and phenotype, or 5) they were classed as  non-European, determined 
by merging the BDR genotypes with data from HapMap Phase 3 
(http://www.sanger.ac.uk/resources/downloads/human/hapmap3.html), linkage disequilibrium 
(LD) pruning the overlapping SNPs such that no pair of SNPs within 1500 bp had r2 > 0.20 and 
visually inspecting the first two genetic principal components along with the known ethnicities 
of the HapMap sample to define European samples (Supplementary Fig. 1). Prior to 
imputation SNPs with high levels of missing data (>5%), Hardy-Weinberg equilibrium P < 
0.001 or minor allele frequency <1% were excluded. The genetic data were then recoded as vcf 
files before uploading to the Michigan Imputation Server (Das et al., 2016) 
(https://imputationserver.sph.umich.edu/index.html#!) which uses  Eagle2 (Loh et al., 2016) to 
phase haplotypes, and Minimac4 (https://genome.sph.umich.edu/wiki/Minimac4) with the 
most recent 1000 Genomes reference panel (phase 3, version 5). Imputed genotypes were then 
filtered with PLINK2.0alpha, excluding SNPs with an R2 INFO score < 0.5 and recoded as 
binary PLINK format. Proceeding with PLINK1.9, samples with >5% missing values, and 
SNPs with >2 alleles, >5% missing values, Hardy-Weinberg equilibrium P < 0.001, or a minor 
allele frequency of <5% were excluded. The final quality controlled imputed set of genotypes 
contained 6,607,832 variants.  
 
Polygenic risk scores 
GWAS results from Kunkle et al (Kunkle et al., 2019) were used to calculate an Alzheimer’s 
disease PRS for each individual. We choose this GWAS as it is based on clinically defined 
cases compared to controls. To separate the effects of APOE from other genetic variants 
associated with Alzheimer’s disease, we excluded the APOE region (chr19:45,116,911–
46,318,605) (Kunkle et al., 2019) from the PRS calculations. We generated PRS using PRSice 
(v2.0)(Choi and O'Reilly, 2019) which ‘clumps’ the Alzheimer’s disease GWAS summary 
statistics using the BDR genotype data such that the most significant variant in each LD block 
was retained. The PRS was then calculated in the target (BDR) dataset for each individual, as 
the number of reference alleles multiplied by the log odds ratio for that SNP (taken from the 
Kunkle et al Alzheimer’s disease GWAS), and then summed across all retained clumped 
variants with an Alzheimer’s disease GWAS P value < PT. A range of P value thresholds (PT) 
were used initially, to generate multiple possible PRS, where the optimal PRS was selected as 
the score that explained the highest proportion of variance (Nagelkerke’s pseudo R2) in 
Alzheimer’s disease case control status.  In this analysis, Alzheimer’s disease cases and 
controls were defined as Braak high (Braak tangle stages V-VI) and low (Braak tangle stages 
0-II) respectively, and PRS was tested using a logistic regression model with the first 8 genetic 
principal components as covariates. In the BDR, cohort the optimal threshold for selecting 
SNPs for the PRS was P < 5x10-8 (Supplementary Fig. 2). Prior to analysis the PRS calculated 
at this threshold was standardized to have a mean of 0 and SD of 1; therefore the interpretation 
is in units of SDs.  
 
APOE genotyping 
The APOE SNPs rs7412 and rs429358 were genotyped with TaqMan assays using standard 
protocols. Where APOE genotype by TaqMan assay was not available, it was generated from 
the NeuroChip data (n = 44). The NeuroChip array includes multiple probes to assay the two 
APOE SNPs; based on the optimal concordance with the Taqman assay (91% concordant 
across assays) we used the probes rs7412.B3 and rs429358.T2 to determine APOE status. In 
all statistical analyses, APOE status was modelled as two numeric variables counting the 
number ε2 alleles and number of ε4 alleles an individual had. Given the rarity of ε2/ε2 genotype 
(only 4 occurrences (0.58%) in this sample), the ε2/ε2 individuals were combined with the 
individuals with one ε2 allele.  
 
Statistical analysis 
All statistical analyses were performed in R version 3.5.2. All analytical code is available via 
GitHub (https://github.com/ejh243/BDR-Genetic-Analyses).  
 
Survival analysis 
To test whether APOE and Alzheimer’s disease PRS were associated with younger age at death, 
we fitted Cox’s proportional hazards models using the R package survival. Three models were 
fitted with age at death as the outcome to test 1) APOE genotype modelled as two variables, 2) 
Alzheimer’s disease PRS and 3) APOE genotype and Alzheimer’s disease PRS simultaneously. 
All models included covariates for sex, BDR centre and 8 genetic principal components.  
 
Genetic analysis of neuropathology and clinical/cognitive status at death 
Genetic associations between either APOE status or Alzheimer’s disease PRS and any of the 
continuous neuropathology variables (Braak tangle stage, Thal β-amyloid stage, CERAD stage, 
Braak Lewy body stage), clinical (CDR global rating) or cognitive status at death (MMSE, 
MoCA) were tested using a linear regression model. TDP-43 proteinopathy as a binary variable 
was analysed with logistic regression, but the model framework was the same. Up to four 
regression models were fitted for each variable. First, the effects of APOE status and 
Alzheimer’s disease PRS were estimated separately using Model 1 and Model 2 below. 
Model 1: 
𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒 ~ 𝐴𝑃𝑂𝐸ε2 + 𝐴𝑃𝑂𝐸ε4 + 𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠 + 𝑔𝑒𝑛𝑒𝑡𝑖𝑐 𝑃𝐶𝑠1−8 
Model 2: 
𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒 ~ 𝑃𝑅𝑆 + 𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠 + 𝑔𝑒𝑛𝑒𝑡𝑖𝑐 𝑃𝐶𝑠1−8 
If APOE (either variable) and PRS were significantly associated with an outcome, then a 
multiple regression analysis was additionally fitted testing APOE and PRS simultaneously to 
confirm these were independent associations (Model 3). 
Model 3: 
𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒 ~ 𝐴𝑃𝑂𝐸ε2 + 𝐴𝑃𝑂𝐸ε4 + 𝑃𝑅𝑆 + 𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠 + 𝑔𝑒𝑛𝑒𝑡𝑖𝑐 𝑃𝐶𝑠1−8 
Finally, an interaction model (Model 4) between APOE and PRS was fitted to test if PRS 
associations differed depending on APOE genotype. 
Model 4: 
𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒 ~ 𝐴𝑃𝑂𝐸ε2 + 𝐴𝑃𝑂𝐸ε4 + 𝑃𝑅𝑆 + 𝐴𝑃𝑂𝐸ε2 ∗ 𝑃𝑅𝑆 + 𝐴𝑃𝑂𝐸ε4 ∗ 𝑃𝑅𝑆 +  𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠
+ 𝑔𝑒𝑛𝑒𝑡𝑖𝑐 𝑃𝐶𝑠1−8 
All analyses included age at death, sex, and BDR centre as covariates and the first eight genetic 
principal components. Analyses for clinical or cognition measures also included a covariate 
that measured the time lapse between the last assessment and death. 
 
Longitudinal clinical and cognition analyses 
To test how APOE and Alzheimer’s disease PRS affected clinical status and cognitive 
trajectories, we fitted multi-level regression models using all available pre-mortem assessment 
data. A time variable was created which measured the number of days after the first visit that 
an assessment took place. Each cognitive variable was then tested as the dependent variable 
against this time variable included as a fixed effect along with covariates for age, sex, BDR 
centre and the first eight genetic principal components and a random effect for individual. To 
test for genetic effects on the cognitive trajectory, either APOE (coded as two variables) or 
Alzheimer’s disease PRS, was included in the model as a main effect and as an interaction with 
time. Models were fitted using the R packages lme4 and lmTest.   
 
Multiple testing 
In total, we tested 12 outcomes against 3 genetic variables. Our outcomes comprised five 
neuropathological variables, one clinical variable at death, two cognitive measures, one 
longitudinal clinical, two longitudinal cognitive measures and a survival analysis of age at 
death. Against these 12 outcomes, we tested 3 genetic variables (Alzheimer’s disease PRS and 
two variables to model APOE genotype). Therefore, we performed a multiple testing correction 
for 36 tests, reporting significant associations as those with P < 0.0014. Given the correlations 
between the neuropathological, clinical and cognitive variables this is likely to be a 
conservative approach. 
 
Data Availability 
Genetic, clinical and cognitive data are available through the Dementia’s Platform UK (DPUK; 
https://www.dementiasplatform.uk/) platform upon application.  
Results 
Both tauopathy and β-amyloidosis are present at high frequencies in the BDR cohort  
In order to profile the effects of both APOE genotype and Alzheimer’s disease PRS, our 
analyses were limited to BDR donors who had undergone neuropathological assessment and 
had NeuroChip array data (n = 693, Table 1). The participants had a mean age at death of 83.5 
years (SD = 9.34 years) and 52.8% were male. Consistent with epidemiological reports, 
females were significantly older at death than males (mean difference = 3.84 years; P = 4.87 x 
10-8). Within this cohort, 57.3% of individuals had dementia at their first assessment (i.e. at 
baseline), with 63.3% of the cohort affected by dementia at death. At recruitment, individuals 
had a mean clinical dementia rating of 1.42 (SD = 1.36), a mean MMSE score of 22.3 (SD = 
8.81) and a mean MoCA score of 17.2 (SD = 10.6). These scores indicate that the majority of 
participants only suffered mild cognitive impairment, although the full range of cognitive 
performance was represented in the cohort. Participants underwent a mean of 2.85 assessments 
(SD = 1.71) prior to death. Individuals who had at least two assessments (N = 486) were 
followed for a mean of 3.40 years (SD = 2.00 years) with a mean of 1.42 years between 
assessments (SD = 0.67 years). Our genetic analyses focused on four semi-quantitative and one 
indicator neuropathology variable.  In 672 samples neurofibrillary tangle (NFT) pathology was 
quantified using Braak NFT stage (Braak and Braak, 1991; Braak et al., 2006) with a mean of 
3.76 (SD = 1.90). Two variables reflecting the extent of β-amyloidosis were considered: β-
amyloid distribution was measured by Thal β-amyloid phase (Thal et al., 2002) with a mean 
value of 3.14 (SD = 1.78) across 612 individuals and neuritic plaque density was scored using 
the CERAD classification (Mirra et al., 1991; Montine et al., 2012) with a mean value of 1.72 
(SD = 1.26) across 634 individuals. α-Synuclein pathology was quantified using Braak Lewy 
body stage, where across 634 individuals the mean was 1.36 (SD = 2.26). TDP-43 status was 
available for 658 individuals, with 150 (22.8%) individuals classed as being TDP-43 positive.  
 
Genetic risk factors for Alzheimer’s disease are associated with increased mortality 
To determine whether higher genetic risk for Alzheimer’s disease was associated with 
increased mortality we analysed survival with Cox’s proportional hazard models (Table 2). 
APOE genotype was modelled as two variables – the number of ε4 alleles and the number of 
ε2 alleles, to distinguish the hypothesized risk effects of ε4 (Corder et al., 1993; Farrer et al., 
1997) from the protective effects of ε2 (Reiman et al., 2020). Analysis of APOE genetic risk 
found that APOE ε4 status was significantly associated with younger age at death, with each 
additional ε4 allele associated with 29% increased risk of death (hazard ratio = 1.29; P = 
9.66x10-5). Alzheimer’s disease PRS was nominally associated with an increased mortality 
(hazard ratio = 1.11; P = 8.97x10-3), although this was not significant after correcting for 
multiple testing.   
 
APOE and Alzheimer’s disease PRS independently influence tauopathy and β-amyloidosis 
The number of APOE ε4 alleles was positively associated (P < 0.00014) with all four semi-
quantitative neuropathology measures (Table 3). The most significant association was with 
Braak neurofibrillary tangle (NFT) stage: each ε4 allele was associated with an increase of 1.16 
Braak NFT stages (P = 4.16x10-24). Associations were also found between ε4 status and Thal 
β-amyloid phase (mean difference per ε4 allele = 0.981 phases; P = 3.96x10-20), neuritic plaque 
density (mean difference per ε4 allele = 0.713 stages; P = 1.03x10-19) and Braak Lewy body 
stage (mean difference per ε4 allele = 0.555 stages; P = 2.64x10-4). Alzheimer’s disease PRS 
was associated with two measures of neuropathology (Table 3): a higher polygenic burden was 
associated with Braak NFT stage (mean difference per SD of PRS = 0.354 stages; P = 1.36x10-
6) and neuritic plaque density (mean difference per SD of PRS = 0.202 stages; P = 5.27x10-5). 
TDP-43 was not associated with either APOE genotype or Alzheimer’s disease PRS. Although 
variants in the APOE region were excluded from the PRS, we tested both APOE and PRS 
against Braak NFT stage and neuritic plaque density simultaneously to confirm that the 
identified associations were independent. The estimated effects of ε4 on both Braak NFT stage 
and neuritic plaque density were unaffected, while the Alzheimer’s disease PRS associations 
were slightly attenuated (Table 3) but remained significant. In addition to an additive model, 
we tested whether there was evidence for a multiplicative effect between Alzheimer’s disease 
PRS and APOE genotype on neuropathological burden to explore the hypothesis that in 
individuals with protective APOE genotypes, Alzheimer’s disease PRS is more important (i.e. 
has a larger effect on neuropathology). In this analysis, none of the five neuropathological 
variables had statistically significant differences across APOE genotype groups (P > 0.05) 
(Supplementary Table 1). Taken together, these results suggest that APOE status and 
Alzheimer’s disease PRS are independently associated with neuropathology, combining in an 
additive manner to influence an individual’s accumulation of tauopathy (NFTs) and β-amyloid 
plaques.  
 
Given that the two distinct molecular pathologies - tauopathy and β-amyloidosis - that define 
Alzheimer’s disease are highly correlated (Supplementary Fig. 3), we wanted to establish 
whether APOE or Alzheimer’s disease PRS had a specific (or primary) effect on a particular 
aspect of neuropathology. To this end, we repeated the analysis of how Alzheimer’s disease 
PRS and APOE influence pathology, sequentially controlling for other neuropathology 
variables. This analysis revealed some interesting patterns. First, after controlling for any of 
the other three quantitative neuropathological variables, Braak Lewy body stage was not 
significantly associated with APOE ε4 (Supplementary Table 2) suggesting that the 
association we detected was largely driven by the fact that individuals with Lewy bodies also 
have NFTs and β-amyloid plaques. Second, after we controlled for Braak NFT stage, neither 
of the plaque measures remained significantly associated with APOE ε4 (Supplementary 
Table 2). In contrast, Braak NFT stage remained significantly associated with APOE ε4 status 
after controlling for plaque variable (adjusted for Thal phase, mean difference per APOE ε4 
allele = 0.468; P = 6.44x10-7; adjusted for neuritic plaque density, mean difference per ε4 allele 
= 0.238; P = 1.82x10-4), albeit with an attenuated magnitude of effect. Considering the two 
measures of plaque burden, only Thal β-amyloid phase remained significantly associated with 
ε4 after controlling for neuritic plaque density (mean difference per ε4 allele = 0.265; P = 
3.42x10-4). Neither Braak NFT stage nor neuritic plaque density remained significantly 
associated with Alzheimer’s disease PRS after controlling for the other measure of pathology 
(Supplementary Table 2). These results indicate that APOE ε4 has a specific influence on 
tauopathy (NFTs) as well as a shared effect on both plaque and NFT development, whereas the 
PRS is more generally associated with an increased burden of Alzheimer’s disease 
neuropathology. 
 
Association between APOE and cognitive performance is confounded by neuropathology 
We determined clinical and cognitive status at death from the final pre-mortem assessment 
(Table 1). Data were available from 639 individuals who had had at least one CDR assessment 
with a mean final score of 1.79 (SD = 1.30) measured a mean of 353 days (SD = 374 days) 
prior to death. In addition, 469 individuals had had at least one MMSE assessment with a mean 
final score of 19.1 (SD = 10.3) measured a mean of 594 days (SD = 521 days) prior to death 
and 270 individuals had a MoCA assessment (mean = 16.1; SD = 11.0) measured a mean of 
617 days (SD = 590 days) prior to death. APOE was significantly associated with dementia 
severity with each ε4 allele associated with an increase of 0.492 (P = 2.14x10-9) in pre-mortem 
CDR score (Table 4). APOE was also significantly associated with lower cognitive 
performance in MMSE prior to death (Table 4) with each ε4 allele being associated with a 
decrease of 4.86 (P = 1.30x10-8). In contrast, Alzheimer’s disease PRS was not significantly 
associated with any of the measures of clinical or cognitive status prior to death. To test whether 
the association between APOE and clinical measures was mediated by neuropathology we 
repeated these analyses including Braak NFT stage as an additional covariate; this variable had 
the largest effect in the genetic analyses described above, and its effect additionally captured 
associations with plaque pathology. In this model, the associations between APOE ε4 and CDR 
or MMSE were attenuated and neither remained significant (Supplementary Table 3). In 
contrast, on retesting Braak NFT stage whilst controlling for the clinical variables in turn, we 
observed that APOE ε4 remained significantly associated (Supplementary Table 3). This 
indicates that the association between APOE and clinical variables is a consequence of an 
increased burden of neuropathology. 
 
APOE ε4 is associated with faster cognitive decline in old age, but this is driven by Alzheimer’s 
disease neuropathological burden 
Participants had a mean of 2.85 (SD = 1.71 visits) clinical assessment visits spread over a mean 
of 3.40 years (SD = 2.00 years) with a mean time between visits of 1.42 years (SD = 0.67 
years). Over the course of all participants' involvement in the BDR study, there was an overall 
decline in clinical status and cognitive performance. On average the CDR increased by a mean 
of 0.139 per year (P = 2.02x10-31), while MMSE declined by a mean of 1.07 per year (P = 
3.00x10-29). APOE genotype was associated with worse cognitive scores at the start of the study 
and faster rates of decline as the study progressed (Table 5). For every ε4 allele, MMSE score 
was 3.19 points lower (P = 4.92x10-5) at the start of the study, and individuals then accumulated 
an additional decrease of 0.803 in their score per allele per year (P = 1.58x10-8). In contrast, 
although APOE was associated with a higher CDR score at the start of the study (mean 
difference per ε4 allele = 0.468; P = 4.34x10-8), there was no significant difference in the 
change in clinical status related to APOE as the study progressed. There was no significant 
association with MoCA scores and APOE genotype. There was no significant association 
between Alzheimer’s disease PRS and longitudinal clinical or cognitive profiles or clinical or 
cognitive status at study entry. On repeating these analyses using the participant’s age rather 
than time in the study, we found no significant linear associations with either cognitive status 
at study entry or performance as the study progressed (Table 5).  
 
Given our previous observation that genetic associations with clinical status and cognition are 
mediated by neuropathology, we wanted to confirm whether the longitudinal analyses were 
similarly affected. First, we tested whether change in clinical status was associated with 
neuropathology measured by Braak NFT stage, independent of genetic status (Supplementary 
Table 5). As expected, those with higher levels of tangle pathology at death had a more severe 
clinical rating, even at the start of the study (mean difference in CDR per Braak NFT stage = 
0.355; P = 7.30x10-42) and declined quicker; each additional Braak NFT stage was associated 
with an additional increase of 0.0247 in CDR per year (P = 3.99x10-5). We observed similar 
results for cognitive performance measured by MMSE; at study entry, each additional Braak 
NFT stage was associated with a decrease of 2.58 in MMSE score (P = 7.27x10-26) and 
participants accumulated an additional decrease of 0.384 in MMSE per Braak NFT stage per 
year (P = 3.90x10-15). Repeating the APOE analysis with a covariate for the potential 
confounder of neuropathology found that in line with the cross-sectional analyses, the 
associations with both clinical severity and cognition were no longer significant after adjusting 
for Braak NFT stage (Supplementary Table 6). These results suggest that cognitive 
performance prior to death, and even many years before death, is a consequence of 
accumulating Alzheimer’s disease neuropathology.   
Discussion 
In this study, we used the longitudinal cognitive and neuropathological assessment data in the 
BDR cohort to investigate how genetic risk factors for Alzheimer’s disease influence the 
accumulation of β-amyloid plaques, tauopathy, synucleinopathy, and TDP-43 proteinopathy, 
and progressive decline in clinical status and cognitive performance. Our results indicate that 
APOE ε4 status has the most dramatic influence on tauopathy (NFT burden) and that although 
APOE genotype is also associated with β-amyloidosis, synucleinopathy and cognition, these 
relationships are largely confounded by their correlation with tangle burden. Furthermore, our 
results indicate that APOE has a specific direct effect on NFT independent of other 
neuropathologies. Although this finding contradicts the predictions of the ‘amyloid cascade 
hypothesis’ in which tau tangle formation is considered secondary to β-amyloid pathology 
(Hardy and Allsop, 1991; Selkoe, 1991), it is consistent with careful neuropathologic studies 
that show that tauopathy can precede beta-amyloidosis, at least in some brain areas 
(Duyckaerts, 2011). Our results also agree with previous research showing that although the 
influence of APOE on tau tangles is largely mediated indirectly through neurobiological 
pathways associated with β-amyloid, approximately one third of its influence on tangle 
development is via an alternative non-amyloid pathway (Yu et al., 2014). Our findings also 
support the 2-process model proposed by Mungas et al (Mungas et al., 2014), according to 
which neocortical NFTs are mediated by β-amyloid deposition and medial temporal lobe NFTs 
and may be the consequence of a separate age-associated process.  
 
In our analysis of pathologies that frequently co-occur with the accumulation of β-amyloid and 
tauopathy, we replicated the positive association between Lewy body burden and the APOE ε4 
allele (Tsuang et al., 2013; Beecham et al., 2014). However, when we adjusted for either β-
amyloid or NFTs, this association was attenuated, indicating that in our sample, the association 
may be a consequence of the higher levels of tau and β-amyloid in individuals with Lewy 
bodies. It should be noted that the majority of participants in our study were free of any Lewy 
body pathology, with 423 individuals (70.8%) having a Braak Lewy body stage of 0. Therefore 
these analyses may be underpowered, particularly in the context of disentangling the effects on 
multiple correlated neuropathology variables. In addition, we were not able to replicate 
associations between APOE genotype and the presence of TDP-43 proteinopathy (Josephs et 
al., 2014; Yang et al., 2018), although the direction of effect was consistent with previous 
reports. Although TDP-43 proteinopathy was not infrequent in the BDR cohort, with 22.8% 
participants classed as positive, our simple binary classification may have decreased our power 
to detect an effect. Although BDR is not limited to a particular dementia subtype, and includes 
unaffected controls, Alzheimer’s disease is the most common form of dementia and therefore 
the sample is enriched for NFT and β-amyloid pathology. To truly establish whether APOE 
genotype has an independent, direct effect on the common comorbidities associated with 
Alzheimer’s disease, such as Lewy bodies and TDP-43 proteinopathy, we will likely require a 
larger number of samples to detect residual effects after accounting for correlations between 
neuropathological variables.  
 
As well as our examination of associations with APOE, we tested the cumulative effect of 
common Alzheimer’s disease-associated genetic variants on neuropathology, clinical status 
and cognition. Given that individual variants only confer a small amount of additional risk, we 
used a combined PRS to improve power. Although Alzheimer’s disease PRS was associated 
with both tauopathy (NFTs) and β-amyloidosis, there was no evidence of independent effects 
on either,  suggesting that, in combination, common genetic variants have a broader, more 
general effect on the neuropathological burden present in Alzheimer’s disease. This contrasts 
with findings from a previous study testing the consequences of an Alzheimer’s disease PRS 
without APOE, which only reported a significant association with NFTs and not β-amyloid 
plaques (Felsky et al., 2018). Of note, in that study the PRS was based on an older GWAS with 
fewer significant association signals, and therefore our study might highlight the additional 
power derived using variants from the latest GWAS for Alzheimer’s disease. While leveraging 
multiple genetic variants into a single PRS is a powerful approach, particularly where sample 
sizes are small, it can be challenging to interpret shared associations. As the PRS is a 
harmonised variable generated in our case from seventeen genetic variants, our results could 
be explained by different subsets of variants being causally associated with the distinct 
pathologies. This explanation fits with results from previous studies that have tested individual 
SNPs associated with Alzheimer’s disease against multiple measures of neuropathology 
reporting some variants having specific effects, while others were associated with multiple 
aspects (Beecham et al., 2014; Mäkelä et al., 2018). Furthermore, it is likely that some genetic 
risk factors do not act via either plaques or tauopathy (NFTs), possibly affecting other aspects 
of neuropathology such as vascular disease which was not included in this study.  
 
We found that clinical and cognitive status at study recruitment and prior to death, in addition 
to decline over the course of the study, are not directly associated with APOE genotype but are 
likely to be a consequence of neuropathological burden and in particular the accumulation of 
NFTs. This concurs with results from a previous study in a slightly larger cohort that focused 
specifically on episodic memory and non-episodic cognition (Yu et al., 2014). Alzheimer’s 
disease-associated cognitive decline is hypothesised to start as much as 17 years prior to death, 
with the rate of decline fastest in those with the most extensive neuropathology; tauopathy, β-
amyloidosis, TDP-43 proteinopathy, and synucleinopathy are all positively associated with 
decline (Boyle et al., 2017). While a strength of our study is the availability of longitudinal 
cognitive data, clinical data was only available for up to three years before death, limiting our 
ability to characterise the effects of neuropathology on cognitive trajectories. Furthermore, 
multiple aspects of neuropathology have been independently negatively associated with 
cognitive performance (Boyle et al., 2013). Although Alzheimer’s disease is characterized by 
β-amyloidosis and tauopathy, it is increasingly apparent that in older cohorts, there may be 
additional comorbidities which potentially confound this relationship (Schneider et al., 2009; 
James et al., 2012; James et al., 2016; Robinson et al., 2018). At present, the presence of 
multiple comorbidities makes it difficult to resolve cause from effect as each comorbidity may 
affect different domains of cognition at different times during pathogenesis. When considering 
the regional presence and global burden of different pathologies, there is extensive variation in 
the specific combination of neuropathological features that an individual develops ultimately 
having a unique effect on their individual cognitive performance over time (Boyle et al., 2018). 
The strengths of the BDR study design, collating repeated measures of cognitive performance 
in addition to standardized protocols for high quality neuropathological assessments in a large 
sample size make it an ideal dataset to ultimately disentangle the role of mixed pathologies on 
cognition and dementia and more extensive analyses will be possible in the future. 
 
Our results should be considered in light of a number of limitations. First, the participants were 
self-selecting, which in line with many other observational cohorts introduces bias into the 
sample; they are from less deprived socio-economic areas and have higher levels of education 
than the general population. Second, consistent with the majority of genetic studies, our 
analysis was limited to participants of European ancestry to remove the biases associated with 
population stratification. Third, we only included a subset of Alzheimer’s disease and related 
neuropathology phenotypes, which were selected for practical reasons in that they were 
observed with sufficient frequency in the current sample. Analyses of rarer phenotypes will be 
possible with subsequent waves of the data as the overall sample size and number of cases 
increases. Fourth, our measures were of global cognition, rather than specific domains. As 
previous studies have found that different pathologies have specific effects of different 
cognitive domains (Yu et al., 2014), this may mean we miss some of the nuances of the 
relationship between neuropathology and cognition. Fifth, to aid interpretation of the analytical 
models we converted semi-quantitative neuropathological variables into continuous variables 
which assume an equal effect between all pairs of consecutive stages. This simplification may 
obscure some more complex patterns in the data but should enable us to pick up general 
correlations which were our primary interest.  Finally, we did not control for severity of 
ischaemic brain damage or any vascular risk factors, which are common in Alzheimer’s disease 
cases and negatively influence cognition. 
 
In summary, our data indicate that APOE influences Alzheimer’s disease neuropathology via 
two independent pathways, one where β-amyloid accumulation correlates with the 
development of tauopathy (NFTs), and a second pathway with direct effects on NFTs 
independent of β-amyloidosis. It is as a consequence of these neuropathological changes that 
cognitive performance is then impaired. The relationship between common genetic variants 
associated with Alzheimer’s disease and neuropathology is more complex, with each individual 
variant potentially having a different effect on neuropathology and cognition. Taken together, 
these results provide insights into how the symptoms of Alzheimer’s disease dementia manifest 
and how genetic risk factors influence the development of pathology. 
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TABLES 
Table 1. Summary of BDR cohort. 
 
  
% Mean SD N 
Demographics Sex (male) 52.8 
  
693 
Age 
 
83.5 9.34 693 
Clinical assessments Number of assessments  2.85 1.71 693 
Time in study (years)  3.40 2.00 486 
Time between 
assessments (years) 
 1.42 0.67 486 
Dementia status at 
first assessment 
Dementia 57.3   693 
MCI/Inconclusive 13.3   693 
No dementia 29.3   693 
Dementia status at 
last assessment 
Dementia 63.3   693 
MCI/Inconclusive 14.2   693 
No dementia 22.5   693 
Neuropathology Braak stage tangle 
 
3.76 1.9 672 
Thal amyloid stage 
 
3.14 1.78 612 
CERAD stage 
 
1.72 1.26 634 
Braak Lewy body stage 
 
1.36 2.26 597 
TDP-43 22.8 
  
658 
Cognitive scores at 
first assessment 
CDR  1.42 1.36 639 
MMSE  22.3 8.81 469 
MOCA  17.2 10.6 270 
Cognitive scores at 
last assessment 
CDR 
 
1.79 1.3 639 
MMSE 
 
19.1 10.3 469 
MOCA 
 
16.1 11 270 
 
  
Table 2. APOE is associated with increased mortality. 
 
Analytical 
model 
APOE 
Polygenic risk score 
Number of ε2 alleles Number of ε4 alleles 
Hazard ratio SE P-value Hazard ratio SE P-value Hazard ratio SE P-value 
Model 1 0.835 0.123 0.142 1.293 0.066 9.66E-05 
   
Model 2 
      
1.105 0.038 8.97E-03 
Model 3 0.839 0.124 0.155 1.292 0.066 1.00E-04 1.106 0.038 8.41E-03 
 
  
Table 3. Common genetic risk factors for Alzheimer’s disease are associated with multiple aspects of neuropathology. 
 
Analytical 
model 
Neuropathological 
variable 
APOE 
Polygenic risk score 
Number of ε 2 alleles Number of ε 4 alleles 
P-value Coefficient %VarExp P-value Coefficient %VarExp P-value Coefficient %VarExp 
Model 1 Braak stage 
tangle 
0.0877 -0.357 0.958 4.16E-24 1.16 15.1    
Thal amyloid 
stage 
0.00333 -0.562 1.54 3.96E-20 0.981 13.5    
CERAD stage 0.0224 -0.329 1.99 1.03E-19 0.713 13.4    
Braak Lewy body 
stage 0.988 -0.00439 0.0809 0.000264 0.555 2.59 
   
TDP-43 0.859 -0.0574 0.00821 0.00158 0.537 2.58    
Model 2 Braak stage 
tangle 
      1.36E-06 3.4 0.354 
Thal amyloid 
stage 
      0.00288 1.1 0.201 
CERAD stage       5.27E-05 2.95 0.202 
Braak Lewy body 
stage 
      0.267 0.167 0.105 
TDP-43       0.315 0.26 0.104 
Model 3 Braak stage 
tangle 
0.0885 -0.3505 0.9580 9.40E-24 1.132 15.119 4.97E-06 0.309 2.465 
CERAD stage 0.0224 -0.3254 1.9865 2.02E-19 0.700 13.402 1.30E-04 0.179 2.192 
 
  
Table 4. APOE is associated with clinical and cognitive status at death. 
 
Analytical 
model 
Cognitive 
variable 
APOE Polygenic risk score 
Number of ε 2 alleles Number of ε 4 alleles 
P-value Coefficient %VarExp P-value Coefficient %VarExp P-value Coefficient %VarExp 
Model 1 CDR 0.706 -0.058 0.336 2.14E-09 0.492 9.83 
   
MMSE 0.693 0.574 0.310 1.30E-08 -4.859 10.05 
   
MOCA 0.876 -0.299 0.157 5.00E-03 -3.403 3.19 
   
Model 2 CDR 
      
0.034 0.109 1.82 
MMSE 
      
0.025 -1.136 2.03 
MOCA 
      
0.785 0.191 0.089 
 
  
Table 5. APOE ε4 is associated with steeper cognitive decline prior to death. 
 
Time 
variable 
Cognitive 
variable 
Time 
APOE Interaction (Time x APOE) 
Number of ε2 alleles Number of ε4 alleles Time x ε2 Time x ε4 
Coefficient P-value Coefficient P-value Coefficient P-value Coefficient P-value Coefficient P-value 
Time 
since 
study 
entry 
(days) 
CDR 2.78E-04 
2.45E-
08 
0.075 0.642 0.468 4.34E-08 -1.34E-04 0.121 1.28E-04 9.83E-03 
MMSE -1.39E-03 
7.50E-
05 
1.209 0.371 -3.195 4.92E-05 -3.73E-04 0.529 -2.20E-03 1.58E-08 
MOCA -1.33E-03 0.146 -0.663 0.710 -2.335 0.040 1.98E-03 0.151 -3.18E-03 0.024 
Age 
(years) 
CDR 2.01E-03 0.797 -0.058 0.965 -0.868 0.216 4.99E-04 0.974 0.017 0.042 
MMSE -0.258 
2.20E-
04 
4.759 0.675 2.574 0.689 -0.040 0.766 -0.086 0.268 
MOCA 0.011 0.904 -4.510 0.783 -5.281 0.616 5.21E-02 0.785 0.031 0.809 
 
 
